PGGICF: Propylene Glycol/Glycerol Intake and Cardiorespiratory Function
Study Details
Study Description
Brief Summary
Propylene glycol/Glycerol intake is increasingly popular. The propylene glycol/glycerol intake effects on cardiorespiratory function are unknown.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
N/A |
Detailed Description
Background. Propylene glycol/Glycerol intake is increasingly popular. The propylene glycol/glycerol intake effects on cardiorespiratory function are unknown. Weaning of propylene glycol/glycerol could allows a quick clearance of propylene glycol/glycerol from the body, with subsequent recovery of cardiorespiratory function.
Specific aim of the research. This research proposal tests the following hypothesis regarding the reversibility of propylene glycol/glycerol and nicotine intake:
-
Propylene glycol/glycerol cessation restores cardiorespiratory function.
-
Chronic propylene glycol/glycerol and propylene glycol/glycerol/nicotine intake induces specific serum and urine proteomics profile, which are partially reversed after cessation.
-
Chronic propylene glycol/glycerol and propylene glycol/glycerol/nicotine intake induces specific serum and urine metabolomics profile, which are partially reversed after cessation.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Nicotine free intake The participant will wean off nicotine during five days before the experimental session. At the start of the experimental session, participants will be exposed to acute propylene glycol/glycerol (mix 50:50) intake. |
Other: Nicotine free intake
The participant will wean off nicotine during five days before the experimental session. At the start of the experimental session, participants will be exposed to acute propylene glycol/glycerol (mix 50:50) intake.
|
Experimental: Nicotine intake The participant will pursuit his regular nicotinic propylene/glycerol intake five days before the experimental session. At the start of the experimental session, participants will be exposed to acute propylene glycol/glycerol/nicotine (mix 50:50) intake. |
Other: Nicotine intake
The participant will pursuit his regular nicotinic propylene/glycerol intake five days before the experimental session. At the start of the experimental session, participants will be exposed to acute propylene glycol/glycerol (mix 50:50) intake.
|
Experimental: Cessation intake The participant will completely stop his regular nicotinic propylene/glycerol intake during five days before the session. At the start of the experimental session, participants will mimick intake with the device turns off. |
Other: Cessation intake
The participant will completely stop his regular nicotinic propylene/glycerol intake during five days before the session. At the start of the experimental session, participants will mimick intake with the device turns off.
|
Outcome Measures
Primary Outcome Measures
- Change in cardiorespiratory function [4 hours]
Continuous monitoring of cardiorespiratory function
Secondary Outcome Measures
- Change in serum and urine proteomics profiles [1 hour]
Serum and urine proteomics
Other Outcome Measures
- Change in serum and exhaled breath condensate metabolomics profiles [1 hour]
Serum and exhaled breath condensate metabolomics
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Subject must be regular propylene glycol/glycerol/nicotine intake users since at least 1 year
-
Subject must be former smokers
Exclusion Criteria:
-
Chronic or acute illness
-
Substance abuse
-
Chronic medication intake
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Erasme Hospital | Brussels | Anderlecht | Belgium | 1070 |
Sponsors and Collaborators
- Université Libre de Bruxelles
Investigators
- Study Director: Philippe van de Borne, MD, PhD, Université Libre de Bruxelles
Study Documents (Full-Text)
More Information
Publications
None provided.- P2016/466 / B406201629930